The ESCALÓN clinical trial demonstrated that a novel injection of cultured human corneal endothelial cells combined with a ROCK inhibitor is a safe and highly effective treatment for corneal edema. Over 12 months, the therapy significantly reduced corneal thickness and improved visual acuity in 88.9% of patients, offering a promising alternative to traditional corneal transplants.
USA
Japan
